Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment

13 Aug 2024

Abstract excerpt

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a worldwide leading cause of liver-related associated morbidities and mortality. Currently, there is a lack of reliable non-invasive biomarkers for an accurate of MASLD. Hence, this study aimed to evidence the functional role of miRNAs as potential biomarkers for MASLD assessment. Data from 55 participants with steatosis (MASLD group) and 45...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endoplasmic Reticulum Stress and Disease
Share to Liver Disease Diagnosis and Treatment
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39138826
DOI: 10.1007/s13105-024-01037-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessmentPMID 39138826Read ↗

MicroRNAs in metabolic dysfunction‐associated diseases: Pathogenesis and therapeutic opportunitiesSemantic proximity Read ↗

Steatosis Non-Invasive Tests Accurately Predict Metabolic Dysfunction-Associated Steatotic Liver Disease, While Fibrosis Non-Invasive Tests Fall Short: Validation in U.S. Adult PopulationSemantic proximity Read ↗

MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver DiseaseSemantic proximity Read ↗

miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular DiseaseSemantic proximity Read ↗

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.Semantic proximity Read ↗

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive DiagnosisSemantic proximity Read ↗

MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectivesSemantic proximity Read ↗

Molecular characterization of liver steatosis through circulating proteins, metabolites and lipidsSemantic proximity Read ↗

GCKR genetic variants and circulating FGF21 define a metabolic risk signature in Metabolic-associated Steatotic Liver diseaseSemantic proximity Read ↗

Clinical and pathological characteristics of metabolic dysfunction-associated steatotic liver disease and the key role of epigenetic regulation: implications for molecular mechanism and treatmentSemantic proximity Read ↗

Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome AnalysisSemantic proximity Read ↗

Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated alcohol‑related liver disease represent distinct clinical phenotypes and fibrosis risks: insights from a population-based Polish cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.